Figure 1

Kaplan-Meier estimates of overall survival. (A) Higher miR-130a expression level was associated with improved survival in temozolomide (TMZ)-treated glioblastoma multiforme(GBM) patients from The Cancer Genome Atlas (TCGA). (B) Higher miR-20a expression level was associated with improved survival in TMZ-treated GBM patients from TCGA. (C) Higher miR-221 expression level was associated with decreased survival in TMZ-treated GBM patients from TCGA. (D) Higher miR-222 expression level was associated with decreased survival in TMZ-treated GBM patients from TCGA. (E) Higher miR-130a expression level was associated with improved survival in TMZ-treated GBM patients from the Chinese Glioma Genome Atlas. (F) The miR-130a level was not correlated with overall survival in patients from TCGA who did not receive treatment with TMZ.